WO2021145325A1 - アルギン酸塩を使用した対象の処置のための組合せ及び方法 - Google Patents
アルギン酸塩を使用した対象の処置のための組合せ及び方法 Download PDFInfo
- Publication number
- WO2021145325A1 WO2021145325A1 PCT/JP2021/000754 JP2021000754W WO2021145325A1 WO 2021145325 A1 WO2021145325 A1 WO 2021145325A1 JP 2021000754 W JP2021000754 W JP 2021000754W WO 2021145325 A1 WO2021145325 A1 WO 2021145325A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- material composition
- alginic acid
- metal salt
- monovalent metal
- Prior art date
Links
- 235000010443 alginic acid Nutrition 0.000 title claims abstract description 98
- 229920000615 alginic acid Polymers 0.000 title claims abstract description 98
- 229960001126 alginic acid Drugs 0.000 title claims abstract description 92
- 239000000783 alginic acid Substances 0.000 title claims abstract description 92
- 238000000034 method Methods 0.000 title description 70
- -1 alginic acid salt Chemical class 0.000 title description 10
- 239000000203 mixture Substances 0.000 claims abstract description 295
- 239000000463 material Substances 0.000 claims abstract description 217
- 229910052751 metal Inorganic materials 0.000 claims abstract description 97
- 239000002184 metal Substances 0.000 claims abstract description 97
- 150000003839 salts Chemical class 0.000 claims abstract description 95
- 150000004781 alginic acids Chemical class 0.000 claims abstract description 90
- 239000006103 coloring component Substances 0.000 claims abstract description 49
- 108010025899 gelatin film Proteins 0.000 claims abstract description 48
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 31
- 239000003431 cross linking reagent Substances 0.000 claims abstract description 28
- 238000004132 cross linking Methods 0.000 claims abstract description 14
- 210000000845 cartilage Anatomy 0.000 claims description 38
- 210000001519 tissue Anatomy 0.000 claims description 37
- 238000005259 measurement Methods 0.000 claims description 32
- 238000003860 storage Methods 0.000 claims description 28
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 claims description 19
- 230000009471 action Effects 0.000 claims description 17
- 239000012530 fluid Substances 0.000 claims description 17
- 238000011156 evaluation Methods 0.000 claims description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 14
- 238000001556 precipitation Methods 0.000 claims description 14
- 230000005540 biological transmission Effects 0.000 claims description 9
- 239000001046 green dye Substances 0.000 claims description 9
- 210000000988 bone and bone Anatomy 0.000 claims description 7
- 210000003041 ligament Anatomy 0.000 claims description 7
- 239000011780 sodium chloride Substances 0.000 claims description 7
- 230000003595 spectral effect Effects 0.000 claims description 7
- 230000005499 meniscus Effects 0.000 claims description 5
- 238000004140 cleaning Methods 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 230000009969 flowable effect Effects 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 description 71
- 239000000243 solution Substances 0.000 description 37
- 239000000975 dye Substances 0.000 description 34
- 238000011282 treatment Methods 0.000 description 23
- 239000002158 endotoxin Substances 0.000 description 21
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 19
- 239000000499 gel Substances 0.000 description 19
- 235000010413 sodium alginate Nutrition 0.000 description 19
- 239000000661 sodium alginate Substances 0.000 description 19
- 229940005550 sodium alginate Drugs 0.000 description 19
- 230000007547 defect Effects 0.000 description 15
- 238000012360 testing method Methods 0.000 description 13
- 239000000049 pigment Substances 0.000 description 12
- 210000001185 bone marrow Anatomy 0.000 description 11
- 230000008859 change Effects 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 241000199919 Phaeophyceae Species 0.000 description 10
- KHLVKKOJDHCJMG-QDBORUFSSA-L indigo carmine Chemical compound [Na+].[Na+].N/1C2=CC=C(S([O-])(=O)=O)C=C2C(=O)C\1=C1/NC2=CC=C(S(=O)(=O)[O-])C=C2C1=O KHLVKKOJDHCJMG-QDBORUFSSA-L 0.000 description 8
- 229960003988 indigo carmine Drugs 0.000 description 8
- 235000012738 indigotine Nutrition 0.000 description 8
- 239000004179 indigotine Substances 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 239000002253 acid Substances 0.000 description 7
- 238000011049 filling Methods 0.000 description 7
- 238000001879 gelation Methods 0.000 description 7
- 238000000569 multi-angle light scattering Methods 0.000 description 7
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 6
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 6
- 229940072056 alginate Drugs 0.000 description 6
- 230000030833 cell death Effects 0.000 description 6
- 238000004090 dissolution Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 241001512709 Lessonia <stramenopiles> Species 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 238000005227 gel permeation chromatography Methods 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000008929 regeneration Effects 0.000 description 5
- 238000011069 regeneration method Methods 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 208000034628 Celiac artery compression syndrome Diseases 0.000 description 4
- 239000004214 Fast Green FCF Substances 0.000 description 4
- RZSYLLSAWYUBPE-UHFFFAOYSA-L Fast green FCF Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC(O)=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 RZSYLLSAWYUBPE-UHFFFAOYSA-L 0.000 description 4
- 239000012901 Milli-Q water Substances 0.000 description 4
- AEMOLEFTQBMNLQ-UHFFFAOYSA-N beta-D-galactopyranuronic acid Natural products OC1OC(C(O)=O)C(O)C(O)C1O AEMOLEFTQBMNLQ-UHFFFAOYSA-N 0.000 description 4
- 239000001110 calcium chloride Substances 0.000 description 4
- 229910001628 calcium chloride Inorganic materials 0.000 description 4
- AEMOLEFTQBMNLQ-YBSDWZGDSA-N d-mannuronic acid Chemical compound O[C@@H]1O[C@@H](C(O)=O)[C@H](O)[C@@H](O)[C@H]1O AEMOLEFTQBMNLQ-YBSDWZGDSA-N 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 235000019240 fast green FCF Nutrition 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 150000004804 polysaccharides Chemical class 0.000 description 4
- 210000000130 stem cell Anatomy 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 241000512260 Ascophyllum Species 0.000 description 3
- 206010061762 Chondropathy Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241001466453 Laminaria Species 0.000 description 3
- 241000239218 Limulus Species 0.000 description 3
- 238000005299 abrasion Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 238000005553 drilling Methods 0.000 description 3
- 230000002439 hemostatic effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- MSXHSNHNTORCAW-MPGIDXPLSA-M sodium;(3s,4s,5s,6r)-3,4,5,6-tetrahydroxyoxane-2-carboxylate Chemical compound [Na+].O[C@@H]1OC(C([O-])=O)[C@@H](O)[C@H](O)[C@@H]1O MSXHSNHNTORCAW-MPGIDXPLSA-M 0.000 description 3
- 239000008279 sol Substances 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 241001474374 Blennius Species 0.000 description 2
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 2
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 2
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 2
- 241001512723 Ecklonia Species 0.000 description 2
- 102000003951 Erythropoietin Human genes 0.000 description 2
- 108090000394 Erythropoietin Proteins 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 2
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 208000032400 Retinal pigmentation Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 208000013201 Stress fracture Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 235000010208 anthocyanin Nutrition 0.000 description 2
- 239000004410 anthocyanin Substances 0.000 description 2
- 229930002877 anthocyanin Natural products 0.000 description 2
- 150000004636 anthocyanins Chemical class 0.000 description 2
- 210000001188 articular cartilage Anatomy 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 229940112869 bone morphogenetic protein Drugs 0.000 description 2
- 230000003848 cartilage regeneration Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229940105423 erythropoietin Drugs 0.000 description 2
- 210000004700 fetal blood Anatomy 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- 210000003035 hyaline cartilage Anatomy 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 150000008040 ionic compounds Chemical class 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000000691 measurement method Methods 0.000 description 2
- 229940117841 methacrylic acid copolymer Drugs 0.000 description 2
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 description 2
- 210000004623 platelet-rich plasma Anatomy 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- 229940071643 prefilled syringe Drugs 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 210000005065 subchondral bone plate Anatomy 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- NPUIQANQRDIHLU-UHFFFAOYSA-N 3-(4-chlorophenyl)sulfonylbutanoic acid Chemical compound OC(=O)CC(C)S(=O)(=O)C1=CC=C(Cl)C=C1 NPUIQANQRDIHLU-UHFFFAOYSA-N 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000512259 Ascophyllum nodosum Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- FRPHFZCDPYBUAU-UHFFFAOYSA-N Bromocresolgreen Chemical compound CC1=C(Br)C(O)=C(Br)C=C1C1(C=2C(=C(Br)C(O)=C(Br)C=2)C)C2=CC=CC=C2S(=O)(=O)O1 FRPHFZCDPYBUAU-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010007710 Cartilage injury Diseases 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- QQILFGKZUJYXGS-UHFFFAOYSA-N Indigo dye Chemical compound C1=CC=C2C(=O)C(C3=C(C4=CC=CC=C4N3)O)=NC2=C1 QQILFGKZUJYXGS-UHFFFAOYSA-N 0.000 description 1
- 235000000177 Indigofera tinctoria Nutrition 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 241001491708 Macrocystis Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- SJEYSFABYSGQBG-UHFFFAOYSA-M Patent blue Chemical compound [Na+].C1=CC(N(CC)CC)=CC=C1C(C=1C(=CC(=CC=1)S([O-])(=O)=O)S([O-])(=O)=O)=C1C=CC(=[N+](CC)CC)C=C1 SJEYSFABYSGQBG-UHFFFAOYSA-M 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229930014669 anthocyanidin Natural products 0.000 description 1
- 150000001453 anthocyanidins Chemical class 0.000 description 1
- 235000008758 anthocyanidins Nutrition 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- JLUGKDWGQPNDGX-UHFFFAOYSA-L azanium;manganese(2+);phosphate Chemical compound [NH4+].[Mn+2].[O-]P([O-])([O-])=O JLUGKDWGQPNDGX-UHFFFAOYSA-L 0.000 description 1
- HKTCVYHTGCMMTJ-UHFFFAOYSA-O benzyl-[4-[[4-[benzyl(ethyl)amino]phenyl]-(5-hydroxy-2,4-disulfophenyl)methylidene]cyclohexa-2,5-dien-1-ylidene]-ethylazanium Chemical compound C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=CC=CC=2)C=2C(=CC(=C(O)C=2)S(O)(=O)=O)S(O)(=O)=O)C=CC=1N(CC)CC1=CC=CC=C1 HKTCVYHTGCMMTJ-UHFFFAOYSA-O 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- YXMMAVURUUXKKN-UHFFFAOYSA-J copper chlorophyll sodium Chemical compound [Na+].[Na+].[Cu+2].[N-]1C2=C(C=3C(C(C)C(=CC=4C(=C(C=C)C(=C5)N=4)C)N=3)CCC([O-])=O)C(C([O-])=O)C([O-])=C2C(C)=C1C=C1C(CC)=C(C)C5=N1 YXMMAVURUUXKKN-UHFFFAOYSA-J 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000001804 debridement Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 125000000664 diazo group Chemical group [N-]=[N+]=[*] 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- FPAYXBWMYIMERV-UHFFFAOYSA-L disodium;5-methyl-2-[[4-(4-methyl-2-sulfonatoanilino)-9,10-dioxoanthracen-1-yl]amino]benzenesulfonate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)C1=CC(C)=CC=C1NC(C=1C(=O)C2=CC=CC=C2C(=O)C=11)=CC=C1NC1=CC=C(C)C=C1S([O-])(=O)=O FPAYXBWMYIMERV-UHFFFAOYSA-L 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000011013 endotoxin removal Methods 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 210000000968 fibrocartilage Anatomy 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000020169 heat generation Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229940097275 indigo Drugs 0.000 description 1
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 230000008407 joint function Effects 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- CEQFOVLGLXCDCX-WUKNDPDISA-N methyl red Chemical compound C1=CC(N(C)C)=CC=C1\N=N\C1=CC=CC=C1C(O)=O CEQFOVLGLXCDCX-WUKNDPDISA-N 0.000 description 1
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 235000010408 potassium alginate Nutrition 0.000 description 1
- 239000000737 potassium alginate Substances 0.000 description 1
- MZYRDLHIWXQJCQ-YZOKENDUSA-L potassium alginate Chemical compound [K+].[K+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O MZYRDLHIWXQJCQ-YZOKENDUSA-L 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- 235000010344 sodium nitrate Nutrition 0.000 description 1
- 239000004317 sodium nitrate Substances 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229960001473 sulfobromophthalein sodium Drugs 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 229950003937 tolonium Drugs 0.000 description 1
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/20—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/734—Alginic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/025—Other specific inorganic materials not covered by A61L27/04 - A61L27/12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/52—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/442—Colorants, dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/06—Flowable or injectable implant compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/06—Materials or treatment for tissue regeneration for cartilage reconstruction, e.g. meniscus
Definitions
- the present invention relates to a treatment technique for a subject using an alginic acid monovalent metal salt, which is useful for cartilage regeneration and the like.
- Articular cartilage such as the knee, has little self-healing ability due to the lack of blood vessels and nerve networks, so if cartilage defects are left untreated, it can lead to joint pain and loss of joint function, often with osteoarthritis of the joint. It may develop into a disease.
- the progression of the condition may result in extensive cartilage defects.
- Treatments for cartilage damage include autologous osteochondral column transplantation (mosaicplasty), pick-drilling (microfracture), drilling, bar-shaving (abrasion), and injured cartilage resection (abrasion). Surgical procedures such as debridement) are known.
- the microfracture method, drilling, and abrasion method are called bone marrow stimulation techniques, which promote bleeding from the bone marrow, induce bone marrow-derived cartilage progenitor cells, and are expected to differentiate into cartilage. be.
- the bone marrow stimulation method has a problem that fibrocartilage having different mechanical properties from the original hyaline cartilage is formed.
- a material in which a monovalent metal salt of alginic acid is dissolved to make it fluid is applied to a defect portion of cartilage tissue, a cross-linking agent is added for fixation to gelate, and the material is left in place for a predetermined period. It is known that the formation of hyaline cartilage is promoted and it is useful as a composition for cartilage regeneration (Patent Document 1).
- Patent Document 2 a composition for local hemostatic activity containing a component having a hemostatic effect and a pigment applicable to the human body is disclosed, and examples of the component having a hemostatic effect include thrombin, sodium alginate, and a vasoconstrictor, and one of the pigments is Blue No. 1 is mentioned.
- Patent Document 3 no specific example of actually using sodium alginate is disclosed.
- the present inventors When using the alginic acid monovalent metal salt, the present inventors have determined whether the alginic acid monovalent metal salt has been applied to a desired location, whether the gelation by a cross-linking agent is sufficient, and whether the once gelled portion is damaged. I realized that it is difficult to confirm. That is, for example, in arthroscopic treatment, the user may use an excessive amount of a material containing an alginic acid monovalent metal salt or a material for gelation thereof due to the uncertainty of fixation. After the administration of the above, it was necessary to take measures such as washing with a sufficient amount of physiological saline or the like. However, it is desirable that the material applied in this way does not spread to the periphery other than the target location as much as possible. It is also desired to save labor in cleaning work.
- an object of the present invention is to realize reliable fixing of a material containing a monovalent metal salt of alginic acid in a fluid state when the material is applied.
- Another object of the present invention is to contain a coloring component and an alginic acid monovalent metal salt, and the coloring component does not precipitate even when stored at a low temperature of about 2 to 8 ° C. for a certain period of time (for example, one month). That is, to provide a composition that can be stably stored.
- the present invention is as follows.
- a first agent (material) composition containing an alginic acid monovalent metal salt and a second agent (material) composition containing a cross-linking agent having an action of cross-linking the alginic acid monovalent metal salt are included.
- the first agent (material) composition is applied to the subject in a fluid state, and the second agent (material) composition is brought into contact with the first agent (material) composition applied to the subject.
- the first agent (material) composition is a combination of the compositions used so as to gel at least a part thereof, and the first agent (material) composition is applied to the subject by further containing a coloring component.
- the combination is characterized in that the state of formation of a gel film on the surface of the first agent (material) composition can be evaluated.
- a first agent (material) composition containing an alginic acid monovalent metal salt and a second agent (material) composition containing a cross-linking agent having an action of cross-linking the alginic acid monovalent metal salt are included.
- the first agent (material) composition is applied to the subject in a fluid state, and the second agent (material) composition is brought into contact with the first agent (material) composition applied to the subject.
- the combination is characterized in that the state of formation of a gel film on the surface of the given first agent (material) composition can be evaluated.
- the evaluation of the formation state of the gel film is an evaluation of the presence or absence of outflow of the fluidized state of the first agent (material) composition applied to the subject.
- the combination according to. [3] The evaluation of the formation state of the gel film is carried out after (1) cleaning the surface of the gel film of the first agent (material) composition applied to the target and / or (2) the target.
- the combination according to the above [3] wherein the pressure on the gel film surface is performed by bringing an instrument into contact with the gel film surface.
- the subject is at least one selected from the group consisting of bone tissue, cartilage tissue, osteochondral tissue, intervertebral disc tissue, meniscus tissue, and ligament, any one of the above [1] to [4].
- [6] The combination according to any one of the above [1] to [5], wherein the first material composition contains a blue to green dye that can be applied to a living body as the coloring component.
- the composition of the first material contains a monovalent metal salt of alginic acid, a blue to green dye that can be applied to a living body, and sodium chloride, and is a composition that can be stored under the conditions of 2 ° C to 8 ° C.
- the coloring component is 0.0005% by mass to 0.05% by mass of Blue No.
- the medium environment is a pH environment.
- the first material composition is a sol or liquid having a pH of 6 or more and a pH of 8 or less
- the second material composition is a liquid having a pH of 4 or more and less than pH 6 or a pH of more than pH 8 and a pH of 12 or less.
- the coloring component is a pH-sensitive dye or a pH-sensitive dye coated with a material for delaying dissolution.
- the present invention provides the following treatment methods for the subject, and for example, the following configurations may be adopted.
- [2-1] A step of applying a first agent (material) composition containing an alginic acid monovalent metal salt and a coloring component to a subject in a fluid state, and an action of cross-linking the alginic acid monovalent metal salt.
- a method for treating the subject which comprises a step of evaluating the formation state of a gel film on the surface of the first agent (material) composition.
- the evaluation of the formation state of the gel film is an evaluation of the presence or absence of outflow of the fluidized state of the first agent (material) composition applied to the subject.
- [2-3] The evaluation of the formation state of the gel film is carried out after (1) cleaning the surface of the gel film of the first agent (material) composition applied to the target and / or (2) the target.
- the subject is at least one selected from the group consisting of bone tissue, cartilage tissue, osteochondral tissue, intervertebral disc tissue, crescent tissue, and ligament, as described above [2-1] to [2-]. 4] The method according to any one of the items. [2-6] In any one of the above [2-1] to [2-5], wherein the first material composition contains a blue to green dye that can be applied to a living body as the coloring component. The method described.
- the first material composition contains an alginic acid monovalent metal salt, a blue to green dye that can be applied to a living body, and sodium chloride, and can be stored under the conditions of 2 ° C to 8 ° C.
- the present invention provides alginic acid monovalent metal salts for use in the following treatments of the subject, for example the following configurations may be employed.
- the first agent (material) and the second agent (material) composition for use in the treatment of the subject which comprises a step of evaluating the formation state of a gel film on the surface of the first agent (material) composition. Combination of.
- bioapplicable compositions are provided, and for example, the following configurations may be adopted.
- [4-1] A biologically applicable composition containing a monovalent metal salt of alginic acid and to be applied to a subject in a fluid state, and is a blue to green color that can be applied to a living body as a coloring component.
- the bioapplyable composition which comprises a dye.
- [4-2] The biological application according to [4-1], wherein the subject is at least one selected from the group consisting of bone tissue, cartilage tissue, osteochondral tissue, intervertebral disc tissue, meniscus tissue, and ligament. Composition.
- a spectrocolorimeter (light source: D65 / 2, measurement mode:) when comparing the composition of the bioapplied composition after storage for one month in a refrigerator at a set temperature of 5 ° C. and before storage.
- the alginic acid monovalent metal salt has a weight average molecular weight (absolute molecular weight) of 10,000 to 1,000,000 as measured by the GPC-MALS method, according to the above [4-1] to [4-6].
- the bioapplicable composition according to any one of the following items.
- [4-9] The bioapplyable composition according to any one of [4-1] to [4-8], wherein the bioapplied composition further contains another monovalent metal salt.
- the bioapplied composition contains a monovalent metal salt of alginic acid, a blue to green dye that can be applied to a living body, and sodium chloride, and can be stored under the conditions of 2 ° C to 8 ° C.
- the bioapplyable composition according to any one of [4-1] to [4-10] which is a composition and is in a solution state or a dry state at the time of storage.
- the bioapplied composition is any one of [4-1] to [4-11], which is a composition for use so that at least a part of the composition is gelled when applied to a subject.
- [4-13] Any one of the above [4-1] to [4-12], wherein the coloring component is 0.0005% by mass to 0.05% by mass of Blue No. 1 (Brilliant Blue FCF).
- the action of cross-linking the monovalent metal salt of alginic acid by containing a coloring component when a material in which a monovalent metal salt of alginic acid is dissolved to be in a fluid state is applied to a subject, the action of cross-linking the monovalent metal salt of alginic acid by containing a coloring component. It is possible to easily confirm whether or not the treatment for gelling and fixing with a cross-linking agent having is sufficient. Thereby, the reliable fixing can be realized.
- a pigment that is permitted to be used in a living body by national regulations as a coloring component that gives visibility that is, a dye that can be applied to a living body, it can be safely used for humans and the like. ..
- compositions containing a coloring component and an alginic acid monovalent metal salt that can be stably stored for a certain period of time under a low temperature condition of about 2 ° C. to 8 ° C. are provided, it is highly safe and easy to use.
- the combination, treatment method, and bioapplyable composition of the present invention have one or more of the above effects.
- the present invention relates to the use of alginic acid monovalent metal salts. Specifically, for example, it has been reported that application of a monovalent metal salt of alginic acid to a damaged or defective part of cartilage promotes regeneration of cartilage tissue at that part (Patent No. 4740369). .. In addition, for example, by applying an alginic acid monovalent metal salt to the cavity after excision (excision) of the intervertebral disc nucleus pulposus as a nucleus pulposus filling material, regeneration of the intervertebral disc nucleus pulposus is promoted and degeneration of the entire intervertebral disc tissue is suppressed. (Patent No. 6487110).
- alginic acid monovalent metal salts are useful for regenerating, repairing, and protecting damaged or defective tissues.
- the combination, method or bioapplicable composition of the present invention is preferably used for injured or defective parts such as bone tissue, cartilage tissue, osteochondral tissue, intervertebral disc tissue, crescent tissue and ligament.
- "damage” also includes “deficiency”, “rupture”, “lesion” and the like.
- the range of organisms is not limited to humans. Non-human organisms such as dogs, cats, pigs, rabbits, sheep, horses, cows, monkeys, birds, mice, rats, guinea pigs, hamsters and the like are also included.
- a composition containing the alginic acid monovalent metal salt is used as the first agent (material).
- a composition containing a cross-linking agent having an action of cross-linking an alginic acid monovalent metal salt is used as the second agent (material). Then, the first agent (material) composition was applied to the subject in a fluid state, and the first agent (material) composition applied to the second agent (material) composition was applied. Contact is made to gel at least a portion of it. As a result, the first agent (material) composition applied to the subject can be fixed and prevented from being displaced or leaking from the applied position.
- the first material composition further contains a coloring component. Then, by observing the colored component as an index, it is possible to evaluate the formation state of the gel film on the surface of the first material composition applied to the subject.
- the “gel film” is a gel formed on the surface of the first material composition by bringing the second material composition containing the cross-linking agent into contact with the first material composition.
- “Can be evaluated” means that the formation state of the gel film on the surface of the first material composition can be visually confirmed, and further, not only by direct visual inspection but also by a microscope or inside. It means that confirmation can be performed through an endoscope (especially in the case of joint application, an arthroscope).
- the composition in a fluid state among the first material compositions applied to the subject flows out is included in the first material composition. It can be carried out by observing the colored components as an index.
- the state of formation of the gel film is evaluated when the first material composition is applied to bone tissue, cartilage tissue, osteochondral tissue, intervertebral disc tissue, meniscus tissue, ligament and the like. It is preferably easy.
- a pigment exhibiting a color tone such as a neutral color system (for example, green) or a cold color system (for example, blue)
- the peripheral tissue, blood (red / yellow color tone), and cartilage (white color tone) are in the visual field in the treatment or the like.
- Shadows blackish color tone
- examples of such pigments include Green No.
- the coloring component used in the present invention is preferably a dye that is permitted to be used in a living body by regulations of the country or the like, that is, a dye that can be applied to a living body, which will be described later.
- the coloring component used in the present invention is used under low temperature conditions of about 2 to 8 ° C. when the first material composition or the bioapplyable composition is prepared according to the description of the present specification. It is preferable that the coloring component can be stably stored for a certain period of time.
- the coloring component may bring about a color tone change according to the medium environment.
- the coloring component when the first material composition applied to the subject flows out, the coloring component is exposed to changes in the medium environment, and the color tone also changes accordingly. It will be easier to know more reliably whether or not it has leaked.
- the formation of the gel film occurs by contact with the first material composition as the second material composition containing the cross-linking agent diffuses near the surface of the first material composition applied to the subject. Therefore, by grasping the situation where the coloring component causes the color tone change, the color tone change reflects the gelling state near the surface of the first material composition applied to the target, and thus the gel. It becomes easier to grasp the formation state of the film.
- a pH-sensitive dye that causes a color tone change according to the pH environment is preferable.
- pH-sensitive dyes include dyes having a color change range on the acidic side and dyes having a color change range on the basic side. Therefore, if desired, a dye having an appropriate color change range can be used. Tables 1 and 2 show typical pH-sensitive dyes.
- the pH of the second material composition when the pH of the second material composition is pH 4 or more and less than pH 6, the pH of the first material composition is set to pH 6 or more and pH 8 or less, and a diazo such as methyl red is used.
- a salton-based pigment such as bromocresol green may be used.
- the pH of the second material composition is more than pH 8 and pH 12 or less, the pH of the first material composition is set to pH 6 or more and pH 8 or less, and a lactone-based dye such as phenolphthalein is used as described above. It can have the effect of visualizing the gel film.
- an anthocyanin-based pigment such as anthocyanidin may be used.
- an appropriate content can be appropriately set as needed, but typically, as an example, 0.0005 w / v% to 1.) of the entire first material composition. It is preferably 0 w / v%, more preferably 0.001 w / v% to 1.0 w / v%, and even more preferably 0.01 w / v% to 1.0 w / v%.
- the content of the coloring component may be 0.0005 w / w% to 1.0 w / w% of the entire first material composition, preferably 0.0005 w / w% to 0. .1w / w%.
- the numerical range indicated by using "-" indicates the range including the numerical values before and after "-" as the minimum value and the maximum value, respectively.
- the pH-sensitive dye may be coated with a material for delaying dissolution.
- a material for delaying dissolution that can be used in such an embodiment, CMEC (carboxymethyl ethyl cellulose), methacrylic acid copolymer S, methacrylic acid copolymer L, or a pH range in which these are dissolved by mixing them in an appropriate ratio is pH 8 Examples thereof include those appropriately adjusted within the range of ⁇ 12.
- a method for coating the dye As a method for coating the dye, a method of microencapsulating using a material for delaying dissolution, a method of kneading with a material for delaying dissolution and then granulating by pulverization or extrusion granulation, and a method of forming fine particles by a spray-drying method. It can be prepared by such a well-known method.
- FIG. 1 illustrates the operation in more detail by taking as an example the case where the above two agents (materials) are applied to a cartilage defect portion as an embodiment of the present invention.
- the first agent (material) composition 1 containing an alginic acid monovalent metal salt is prepared into a fluid composition in a sol or liquid state, and the cartilage defect portion 2 is prepared with an injector such as a syringe (not shown).
- the cartilage defect portion 2 may be subjected to, for example, a bone marrow stimulation technique that promotes bleeding from the bone marrow, induces cartilage progenitor cells derived from the bone marrow, and expects differentiation into cartilage.
- a bone marrow stimulation technique specifically, one or a plurality of holes reaching the subchondral bone with a diameter of about 1.5 mm may be formed by using a pick, a power drill, or the like.
- one or a plurality of holes having a diameter of about 1.5 mm and not reaching the subchondral bone may be formed. ..
- the cross-linking agent contained in the second agent (material) composition 3 diffuses to the entire surface of the first agent (material) composition 1 together with the diffusion of the second agent (material) composition 3 (in FIG. 1, in FIG. 1).
- the first agent (the portion indicated by the reference numeral “1a") is filled in the cartilage defect portion 2 so as to exert a cross-linking action on the alginic acid monovalent metal salt so that the opening of the cartilage defect portion 2 is covered.
- Material A gel film is formed on the surface of the composition 1 (FIG. 1c).
- the first agent (material) composition 1 which was in a fluid state when filling the cartilage defect portion 2 is fixed to the cartilage defect portion 2, and the application position thereof is displaced. Leakage from the cartilage defect 2 can be prevented.
- the inside of the first agent (material) composition 1 other than the vicinity of the surface does not necessarily have to be gelled. Rather, non-gelation may favor the migration and organization of progenitor cells that form the basis of tissue.
- the first material composition containing an alginic acid monovalent metal salt is applied to the target, and then the second material composition containing a cross-linking agent having an action of cross-linking the alginic acid monovalent metal salt.
- the method for causing the action is not particularly limited, but for example, a typical surgical method for a living body includes a treatment in which the affected area is incised under direct vision. Alternatively, a percutaneous surgical method (incision of about 5 mm) may be used. Alternatively, as a less invasive procedure, the procedure is performed under a microscope (about 3 to 4 cm incision) or under an endoscope (arthroscope, especially in the case of joint application) (about 1 to 2 cm incision). You may.
- the visibility at the time of application of the first material composition is improved, so that the field of view is similar to that of the treatment under a microscope or an endoscope (particularly, in the case of joint application, an arthroscope).
- the merit is especially great when the technique with limited is adopted. For example, in a narrow joint space under arthroscopy, when the first material composition 1 is injected into the cartilage defect portion 2 until it becomes the same height as the surrounding tissue, whether the composition can be properly filled if it is transparent. I don't know and the procedure is difficult. By coloring the composition, the state of filling can be seen, so that the composition can be filled appropriately.
- the activity of the first material composition on the second material composition can be evaluated in advance by an in vitro test. That is, using the same usage ratio as in actual use, for example, 500 ⁇ L of the first material composition was placed in a test tube having a diameter of 6 mm, and the cross-linking agent was prepared at a predetermined usage ratio. After filling the product from above and allowing it to stand for 1 hour, the surface portion of the composition in the test tube is gelled, while at least 50% of the volume of the composition in the test tube is not gelled and is gelled. The missing portion may be evaluated in advance, for example, at least 50% of the volume of the composition in the test tube can be aspirated with a syringe equipped with a 21G injection needle.
- Alginic acid monovalent metal salt Alginic acid is a biodegradable high molecular weight polysaccharide, which is a polymer in which two types of uronic acids, D-mannuronic acid (M) and L-gluuronic acid (G), are linearly polymerized. be. More specifically, the homopolymer fraction of D-mannuronic acid (MM fraction), the homopolymer fraction of L-glulonic acid (GG fraction), and D-mannuronic acid and L-gluuronic acid are randomly arranged. It is a block copolymer in which the obtained fractions (MG fractions) are arbitrarily bonded.
- the composition ratio (M / G ratio) of D-mannuronic acid and L-gluuronic acid of alginic acid differs mainly depending on the type of organism from which seaweed is derived, and is also affected by the habitat and season of the organism. It ranges from a high G type with an M / G ratio of about 0.4 to a high M type with an M / G ratio of about 5.
- Alginic acid may be of natural origin or a synthetic product, but for example, naturally derived alginic acid derived from brown algae or the like may be used.
- Alginic acid-containing brown algae thrive in coastal areas around the world, but in practice, the brown algae that can be used as raw materials are limited, such as Lessonia in South America, Macrocistis in North America, Laminaria and Ascophyllum in Europe, Australia's Daviria is a typical example.
- the genus Lessonia, the genus Macrocytis, the genus Laminaria (the genus Kelp), the genus Ascophyllum, the genus Durvillea, the genus Ecklonia, the genus Ecklonia, etc. Can be mentioned.
- a monovalent metal salt of alginic acid is used.
- the alginic acid monovalent metal salt has good solubility and dissolution stability, and is suitable for being applied to a target such as a living tissue in a state of being dissolved in a solvent such as water and having fluidity. It is a form.
- the alginic acid monovalent metal salt can be prepared by using the above-mentioned brown algae by a known method such as an acid method or a calcium method, or a method similar thereto.
- the monovalent metal salt of alginate include sodium alginate and potassium alginate, but sodium alginate, which is commercially available, is particularly preferable.
- the weight average molecular weight is generally 10,000 to 10 million, preferably 20,000 to 8 million, and more preferably 5. It is in the range of 10,000 to 5 million.
- the molecular weight of the alginic acid monovalent metal salt used in the present invention can be measured according to a conventional method.
- a typical condition when gel permeation chromatography is used for molecular weight measurement for example, GMPW-XL ⁇ 2 + G2500PW-XL (7.8 mm ID ⁇ 300 mm) can be used as a column.
- GMPW-XL ⁇ 2 + G2500PW-XL (7.8 mm ID ⁇ 300 mm can be used as a column.
- a 200 mM aqueous sodium nitrate solution can be used, and as a molecular weight standard, for example, pullulan can be used.
- an RI detector and a light scattering detector (MALS) can be used as detectors.
- the molecular weight of the alginic acid monovalent metal salt used in the present invention for example, the weight average molecular weight measured by gel permeation chromatography (GPC) or gel filtration chromatography (collectively referred to as size exclusion chromatography) is preferable.
- GPC gel permeation chromatography
- size exclusion chromatography size exclusion chromatography
- the absolute weight average molecular weight can be measured.
- the weight average molecular weight (absolute molecular weight) measured by such a GPC-MALS method is preferably 10,000 or more, more preferably 80,000 or more, still more preferably 90,000.
- the above is more preferably 1 million or less, more preferably 800,000 or less, still more preferably 700,000 or less, and particularly preferably 500,000 or less.
- the preferred range is 10,000 to 1,000,000, more preferably 80,000 to 800,000, even more preferably 90,000 to 700,000, and particularly preferably 90,000 to 500,000.
- a measurement error of 10 to 20% or more may occur.
- the value may fluctuate in the range of 320,000 to 480,000 for 400,000, 400,000 to 600,000 for 500,000, and 800 to 1.2 million for 1,000,000.
- alginic acid monovalent metal salt tends to have a large molecular weight and a high apparent viscosity, and after undergoing processes such as drying and purification by heat, the molecular weight becomes small and the apparent viscosity is low.
- Alginic acid monovalent metal salts having different molecular weights can be produced by methods such as controlling conditions such as temperature in the production process, selecting brown algae as a raw material, and fractionating the molecular weight in the production process. Further, it is also possible to obtain an alginic acid monovalent metal salt having a desired molecular weight by mixing it with another lot of alginic acid monovalent metal salt having a different molecular weight or viscosity.
- the quality of the alginic acid monovalent metal salt used in the present invention can be tested not only by the above-mentioned molecular weight but also by the characteristics of viscosity.
- the viscosity when dissolved in Milli-Q water to obtain a solution having a concentration of 1 w / w% and the viscosity was measured at 20 ° C. using a cone plate viscometer was 40 mPa ⁇ s to 800 mPa ⁇ ⁇ . It is preferably s, and more preferably 50 mPa ⁇ s to 600 mPa ⁇ s.
- the alginic acid monovalent metal salt used in the present invention is preferably treated with low endotoxin. According to this, it can be safely applied to a target such as a living tissue without causing fever or the like.
- the endotoxin level can be confirmed by a known method, for example, it can be measured by a method using Limulus reagent (LAL), a method using Entspecy (registered trademark) ES-24S set (Seikagaku Corporation), or the like. ..
- the low endotoxin treatment can be performed by a known method known for a polymer material derived from a natural product or a method similar thereto.
- a known method known for a polymer material derived from a natural product or a method similar thereto for example, the method of Suga et al. For purifying sodium hyaluronate (see, for example, JP-A-9-324001) and the method of Yoshida et al. For purifying ⁇ -1,3-glucan (for example, JP-A-8-269102).
- William et al.'S method for purifying high molecular weight salts such as alginate and gellan gum (see, eg, JP-A-2002-530440), James et al.'S method for purifying polysaccharides (eg, International Publication No.
- the low endotoxin treatment of the present invention is not limited to these, such as washing, filtration by a filter (endotoxin removal filter, charged filter, etc.), extrafiltration, column (endotoxin adsorption affinity column, gel filtration column, column with ion exchange resin, etc.) ), Adsorption to hydrophobic substances, resins or activated charcoal, organic solvent treatment (extraction with organic solvent, precipitation / precipitation by addition of organic solvent, etc.), surfactant treatment (for example, JP-A-2005-036036) It can be carried out by a known method such as (see Gazette) or a combination thereof as appropriate. A known method such as centrifugation may be appropriately combined with these treatment steps. It is desirable to appropriately select it according to the type of alginic acid monovalent metal salt and the like.
- the method of low endotoxin treatment is not particularly limited, but as a result, the endotoxin content is preferably 500 endotoxin units (EU) / g or less, preferably 100 EU, when endotoxin measurement with Limulus reagent (LAL) is performed. It is more preferably / g or less, even more preferably 50 EU / g or less, and particularly preferably 30 EU / g or less.
- the low-endotoxin-treated sodium alginate can be obtained from commercially available products such as SeaMatrix (registered trademark) (Mochida Pharmaceutical Co., Ltd.) and PRONOVATMUP LVG (FMC BioPolymer).
- cross-linking agent having an action of cross-linking a monovalent metal salt of alginic acid is used.
- a cross-linking agent having an action of cross-linking a monovalent metal salt of alginic acid is used.
- divalent or higher valent metal ionic compounds such as Ca 2+ , Mg 2+ , Ba 2+ , and Sr 2+.
- examples of the divalent or higher valent metal ion compound include CaCl 2 , MgCl 2 , CaSO 4 , and BaCl 2 , but CaCl is particularly available because of its availability and gel strength. Two solutions are preferred.
- the first agent (material) composition in the present invention may contain the above-mentioned alginic acid monovalent metal salt and the coloring component described in the present specification, and is particularly pharmaceutical.
- a solution once prepared may be provided in a dry state by freeze-drying or the like.
- the solvent for that purpose is not particularly limited, and examples thereof include purified water, distilled water, ion-exchanged water, milliQ water, physiological saline, and phosphate buffered saline (PBS). These are preferably sterilized and preferably treated with low endotoxin.
- Milli-Q water can be sterilized by filtration before use. That is, the first material composition is preferably in a solution state or a dry state when it is stored (or provided).
- the first material composition in the present invention may contain a component other than the above-mentioned alginic acid monovalent metal salt, and in order to obtain the above-mentioned first material composition by a mixing operation thereof, etc. It is desirable to perform this operation in an environment with low endotoxin and bacterial levels.
- the operation is preferably performed on a clean bench using sterile instruments, and the instruments used may be treated with a commercially available endotoxin remover.
- the first material composition in the present invention has a property of being applied to an object such as a living tissue, for example, having a fluidity that allows the composition to be allowed to stand at 20 ° C. for 1 hour and then injected with a 21 G injection needle. Is desirable. At this time, if the viscosity is too low, the adhesion to the surrounding tissue of the applied site may be weakened. Therefore, the apparent viscosity is not particularly limited, but is preferably 10 mPa ⁇ s or more, more preferably 100 mPa ⁇ s or more, and further. It is preferably 200 mPa ⁇ s or more, and particularly preferably 500 mPa ⁇ s or more.
- the apparent viscosity is preferably 50,000 mPa ⁇ s or less, more preferably 20,000 mPa ⁇ s or less, and further preferably 10,000 mPa ⁇ s or less.
- the apparent viscosity is 20000 mPa ⁇ s or less, it can be more easily applied with a syringe or the like.
- the apparent viscosity is 20000 mPa ⁇ s or more, it can be applied by using a pressure type or electric type filling device or other means.
- the preferred range of the composition of the present invention is 10 mPa ⁇ s to 50,000 mPa ⁇ s, more preferably 100 mPa ⁇ s to 30,000 mPa ⁇ s, still more preferably 200 mPa ⁇ s to 20000 mPa ⁇ s, still more preferably 500 mPa ⁇ s to 20000 mPa. ⁇ S, particularly preferably 700 mPa ⁇ s to 20000 mPa ⁇ s. In another preferred embodiment, it may be 500 mPa ⁇ s to 10000 mPa ⁇ s, or 2000 mPa ⁇ s to 10000 mPa ⁇ s. Some, but not limited to, compositions of the present invention have viscosities that can also be applied to the subject with a syringe or the like.
- the apparent viscosity of the first material composition can be measured according to a conventional method.
- a co-axis double-cylindrical rotational viscometer, a single cylindrical rotational viscometer (Brookfield type viscometer), a cone-plate type rotational viscometer (cone plate type viscometer), etc. by the rotational viscometer method are used.
- the apparent viscosity should be set so that it is insoluble in a solvent such as cells in order to accurately measure the viscosity. Is preferable.
- the apparent viscosity of the first material composition is more preferably measured using a cone plate type viscometer and a sensor 35/1 (cone diameter 35 mm, 1 °).
- the sample solution is prepared using Milli-Q water.
- the measurement temperature is 20 ° C.
- the rotation speed of the cone plate type viscometer is 1 rpm when measuring a 1% solution of alginic acid monovalent metal salt, and 0.5 rpm when measuring a 2% solution, and this is used as a guide for determination.
- the reading time is measured for 2 minutes in the case of measuring a 1% solution of alginic acid monovalent metal salt, and is an average value from 1 minute to 2 minutes after the start. In the case of 2% solution measurement, measure for 2.5 minutes and use the average value from 0.5 minutes to 2.5 minutes after the start.
- the test value shall be the average value of three measurements.
- the apparent viscosity of the first material composition can be adjusted by, for example, the concentration of the alginic acid monovalent metal salt in the composition, the molecular weight of the alginic acid monovalent metal salt used, the M / G ratio, or the like. Alternatively, it can also be adjusted by using two or more kinds of alginic acid monovalent metal salts of different lots having properties of different molecular weights or viscosities in combination.
- the apparent viscosity of the first material composition tends to increase when the concentration of the alginic acid monovalent metal salt in the composition is high, and the apparent viscosity tends to decrease when the concentration is low. be. Further, when the molecular weight of the alginic acid monovalent metal salt is large, the apparent viscosity tends to be high, and when the molecular weight is small, the apparent viscosity tends to be low. In addition, the apparent viscosity is affected by the M / G ratio of the alginic acid monovalent metal salt used. In this respect, the M / G ratio of the alginic acid monovalent metal salt used in the present invention is preferably 0.1 to 5.0, more preferably 0.1 to 4.0, and 0.2. It is even more preferably ⁇ 3.5.
- the alginic acid monovalent metal salt used in the present invention is preferably derived from brown algae belonging to the genus Lessonia, Macrocystis, Laminaria, Ascophyllum, Derbilia, etc., and is preferably derived from the genus Lessonia. It is more preferable that it is derived from brown algae belonging to the genus, and it is particularly preferable that it is derived from Lessonia nigressens.
- the content of the monovalent metal salt of alginic acid is affected by the molecular weight in order to have a property of a certain viscosity, and therefore cannot be unequivocally determined, but 0.1 w / of the entire composition of the first material in the present invention. It is preferably v% or more, more preferably 0.5 w / v% or more, still more preferably 1 w / v% or more. More specifically, the concentration of the alginic acid monovalent metal salt is preferably 0.5 w / v% to 5 w / v%, more preferably 1 w / v% to 5 w / v%, and even more preferably 1 w / v% to 3 w.
- the concentration of the alginic acid monovalent metal salt is preferably 0.5 w / w% to 5 w / w%, more preferably 1 w / w% to 5 w / w%, still more preferably 1 w / w%. It may be ⁇ 3w / w%, particularly preferably 1.5w / w% ⁇ 2.5w / w%.
- the first material composition in the present invention is a monovalent alginate metal subjected to the above-mentioned low endotoxin treatment from the viewpoint of being safely applied to a target such as a living tissue without causing heat generation or the like.
- the endotoxin content of the composition using a salt is preferably 500 endotoxin units (EU) / g or less, preferably 300 EU / g or less, when endotoxin measurement with Limulus reagent (LAL) is performed. It is more preferably 150 EU / g or less, and particularly preferably 100 EU / g or less.
- the first material composition may contain cells.
- cells include nucleus pulposus cells, stem cells, stromal cells, mesenchymal stem cells, bone marrow stromal cells, and the like, and the origin is not particularly limited, but includes disc nucleus pulposus, bone marrow, adipose tissue, umbilical cord blood, and the like. Can be mentioned.
- ES cells and iPS cells can also be mentioned as cells.
- the cells to be used are collected from the nucleus pulposus, bone marrow, adipose tissue, umbilical cord blood, etc., as necessary, and subjected to a treatment for concentrating the target cells or a treatment for culturing to increase the number of cells.
- Prepared cells can be used. And, although it depends on the type of cells, typically, for example, 1 ⁇ 10 4 cells / ml or more, or 1 ⁇ 10 5 cells / ml or more, preferably 1 ⁇ 10 4 in the first material composition. It can contain cells / ml to 1 ⁇ 10 7 cells / ml.
- the cells may be commercially available and used.
- the first material composition may contain a factor that promotes cell growth.
- factors include BMP (Bone morphogenetic protein), FGF (Fibroblast growth factor), VEGF (Vascular endothelial growth factor), HGF (Hepatocyte growth factor), TGF- ⁇ (Transforming growth factor- ⁇ ), and IGF.
- BMP Bismaleic acid
- FGF Fibroblast growth factor
- VEGF Vascular endothelial growth factor
- HGF Hepatocyte growth factor
- TGF- ⁇ Transforming growth factor- ⁇
- IGF IGF.
- -1 Insulin-like growth factor-1
- PDGF Platinum-derived growth factor
- CDMP Cartilage-derived-morphogenetic protein
- CSF Coldy stimulating factor
- EPO Erythropoietin
- IL Interleukin
- PRP Platelet rich plasma
- SOX transcription factor
- IF Interferon
- the first material composition does not contain these factors. Even when the growth factor is not contained, the action and effect of alginic acid monovalent metal salt such as regeneration of cartilage tissue is sufficiently good, and the safety is higher than that in the case of actively suppressing cell death.
- the first material composition may contain a factor that suppresses cell death.
- factors that cause cell death include Caspase, TNF ⁇ , and the like, and examples of factors that suppress these include antibodies, siRNA, and the like. These factors that suppress cell death may be produced by a recombinant method or may be purified from a protein composition.
- the first material composition does not contain these factors. Even when the factor that suppresses cell death is not contained, the action and effect of alginic acid monovalent metal salt such as regeneration of cartilage tissue is sufficiently good, and it is safer than the case where cell death is actively suppressed. Is also expensive.
- the first material composition is optionally further tensioned with other pharmaceutically active ingredients, stabilizers, emulsifiers, osmoregulators, buffers, isotonic.
- Ingredients commonly used in pharmaceuticals such as conventional ingredients such as agents, preservatives, and soothing agents, may be included.
- the first material composition may contain a monovalent metal salt such as sodium chloride or potassium chloride, or an ammonium salt such as ammonium chloride, and is preferably a monovalent metal salt. , More preferably sodium chloride.
- the first material composition basically does not necessarily require a cross-linking agent that gels the composition.
- the first material composition may contain an amount of a cross-linking agent that causes the composition to gel only after a certain period of time.
- the fixed time here is not particularly limited, but is preferably about 30 minutes to 12 hours.
- the absence of an amount of cross-linking agent that gels the composition may be indicated, for example, by allowing the composition to stand at 20 ° C. for 1 hour and then injecting with a syringe equipped with a 21 G needle.
- the first material composition does not contain a cross-linking agent.
- the second agent (material) composition in the present invention may be any one containing the above-mentioned cross-linking agent, and the pharmaceutical form thereof is not particularly limited.
- a solution once prepared may be provided in a dry state by freeze-drying or the like.
- an injector such as a syringe at the time of use. Therefore, it is preferable to use it in a liquid state at the time of application.
- the solvent for that purpose is not particularly limited, and examples thereof include purified water, distilled water, ion-exchanged water, milliQ water, physiological saline, and phosphate buffered saline (PBS). These are preferably sterilized and preferably treated with low endotoxin.
- Milli-Q water can be sterilized by filtration before use.
- the second material composition in the present invention may contain a component other than the above-mentioned cross-linking agent, and the operation for obtaining the above-mentioned second material composition such as the mixing operation thereof is performed by the above-mentioned first material composition.
- the lumber composition it is desirable to carry out in an environment with low endotoxin and bacterial levels.
- the operation is preferably performed on a clean bench using sterile instruments, and the instruments used may be treated with a commercially available endotoxin remover.
- the concentration of the cross-linking agent in the second material composition and the like may be appropriately set according to the type of the cross-linking agent used and the like.
- concentration varies depending on the concentration and molecular weight of the alginic acid monovalent metal salt of the first material composition to be applied, and is generally determined.
- it may be preferably 10 mM to 1000 mM, more preferably 25 mM to 200 mM, and particularly preferably 50 mM to 150 mM.
- Bioapplicable Compositions in another aspect of the present invention, further provides bioapplyable compositions.
- biologically applicable composition is defined as a coloring component in the combination of the compositions described above or the first material composition in the treatment method, and its use in a living body is permitted by the regulations of the country and the like.
- a dye that is present that is, a dye that can be applied to a living body. Therefore, “bioapplicable composition” is a form of "first material composition”, and the term “first material composition” is used to include “bioapplicable composition", unless otherwise specified.
- the "first material composition” can be read and used as a “biologically applicable composition”.
- this bioapplyable composition contains a coloring component and a monovalent metal salt of alginic acid and is applied to a subject in a fluid state, and preferably at least a part of the composition gels when applied to the subject. It is used as a.
- a coloring component By containing a coloring component, the state of gelation when applied to the subject can be reliably visually recognized, and further, the use as a coloring component in a living body is permitted by the regulations of the national government.
- a dye that has been used that is, a dye that can be applied to a living body, it can be safely used for humans and the like.
- Dyes that can be applied to living organisms according to national regulations include, for example, dyes approved for use in pharmaceuticals, quasi-drugs, and cosmetics by the Ministry of Health, Labor and Welfare in Japan, and by the FDA in the United States. , Pigments approved for use in pharmaceuticals, medical devices, cosmetics, etc.
- the coloring component makes it easy to evaluate the formation state of the gel film when the bioapplyable composition is applied to bone tissue, cartilage tissue, osteochondral tissue, intervertebral disc tissue, meniscus tissue, ligament, etc. Is preferable, and from the viewpoint of distinguishability, a blue to green dye is preferable. Examples of such coloring components include Green No. 3 (Fast Green FCF), Blue No. 1 (Brilliant Blue FCF), Blue No.
- Green No. 2 Indigo Carmine
- Green No. 201 Aligna Cynthianin Green F
- Green 202 No.
- Kinizarin Green SS Blue No. 201 (Indigo)
- Blue No. 202 Patent Blue NA
- Blue No. 203 Patent Blue CA
- Green No. 3 Green Fast Green FCF
- Blue No. 1 Brown Blue FCF
- the above-mentioned dye is contained at a concentration that gives visibility by the dye and at a concentration that does not cause precipitation during refrigerated storage. Is preferable. According to this, even when the dye contained in the composition as a coloring component that gives visibility is stored in a refrigerator before being applied to the subject, its dispersibility or uniformity is kept stable. , The state of gelation when applied to the subject can be visually recognized more reliably.
- the concentration of the dye in the above composition is a concentration that gives visibility may be confirmed visually, but may be evaluated by measuring the color.
- the L * a * b * color space used to represent the color of an object was standardized by the International Commission on Illumination (CIE) in 1976, and is also a Japanese Industrial Standard (JIS Z 8781-4) in Japan. It is a color system adopted in.
- L * represents the lightness of the color
- the chromaticity (hue and saturation) is represented by the numerical values of a * and b *.
- a * and b * indicate the color direction
- a * indicates the red direction
- -a * indicates the green direction
- b * indicates the yellow direction
- -b * indicates the blue direction.
- the range of the L * a * b * color system of the 2 w / w% sodium alginate solution containing Blue No. 1 at a concentration of 0.001 to 0.01 w / w% is that the light source is D65. / 2
- L * (brightness) is when measured in a normal temperature (15 to 25 ° C) environment using a spectral color difference meter (SE-6000) (manufactured by Nippon Denshoku Kogyo Co., Ltd.) with the measurement mode as transmission measurement. 40 to 80, a * was -40 to -5 (green direction), and b * was -60 to -20 (blue direction).
- the color is in this range, it is easy to distinguish it from cartilage and surrounding tissues, and it is easy to evaluate the formation state of the gel film.
- L * blueness
- the black tendency of the composition becomes strong, and it is difficult to distinguish due to the shadow at the time of application.
- L * is too high (close to 100)
- the white tendency of the composition becomes strong, and it becomes difficult to distinguish it from white cartilage or the like.
- the 2 w / w% sodium alginate solution containing Blue No. 1 at a concentration of 0.1 w / w% has a strong tendency to be black and is not suitable for use in the present invention.
- the range of color values in the preferable L * a * b * color system of the first material composition or the bioapplyable composition of the present invention is 40 to 80 for L * (brightness) and -40 to 0 for a *.
- B * are -60 to -20.
- the color difference in which a human has an image of a clearly different color name is about 13 to 25 as the value of the color difference ⁇ E represented by the following formula (1).
- Most parts of cartilage tissue, intervertebral disc tissue, and surrounding tissues are white and red (a * is a positive value) to yellow (b * is a positive value), and the a * and b * values are. , Each is often a positive value.
- the first material composition or the bioapplyable composition of the present invention has a * of -40 to 0 and b * of -60 to -20, and it can be seen that a sufficient difference in color tone can be obtained.
- L1 *, a1 *, and b1 * are the values of the L * a * b * color space of the comparative control, and L2 *, a2 *, and b2 * are the values when the target sample is measured. Each value of the L * a * b * color space of.
- the L *, a *, and b * values can be measured using, for example, a spectroscopic color difference meter (“SE-6000”, manufactured by Nippon Denshoku Industries Co., Ltd.) or the like.
- the spectroscopic color difference meter may also be called a spectroscopic colorimeter or the like.
- the composition is used for a certain period of time (for example, 1 day, 1 week, 2 weeks, 3 weeks, 1). Months, 2 months, 3 months, 4 months, 5 months, 6 months, 1 year, 2 years, 3 years, etc.), refrigerator (for example, set temperature: 2 ° C, 3 ° C, 4 ° C, After storing at 5 ° C, 6 ° C, 7 ° C, 8 ° C, etc.), visually observe the presence or absence of precipitation, or after filtering with a filter (0.45 ⁇ m pore), measure the color difference before and after the filtration. You can make a judgment.
- the composition is stored in a refrigerator at a set temperature of 5 ° C. for one month for evaluation.
- a state in which the color tone becomes invisible can be detected as a decrease in the value of the color difference represented by the above formula (1). That is, when the pigment is precipitated, the amount of the dissolved pigment is reduced, and the degree of color tone is lowered.
- the evaluation may be made by focusing on a specific chromaticity value such as an a * value or a b * value. Therefore, as the concentration of the coloring component in the above composition, for example, if the coloring component is blue, pay attention to the b * value and store it as the b * value after storage in a refrigerator set at 5 ° C. for one month. A concentration is preferable so that the difference from the previous b * value is kept in the range of 25 or less.
- the color of the first material composition or the bioapplyable composition of the present invention is stable even after storage for a certain period of time as described above.
- the value of the color difference ⁇ E between the composition after being stored in a refrigerator at a set temperature of 5 ° C. for one month and the composition before storage is preferably 35 or less, more preferably. It is 30 or less.
- the first material composition or the bioapplyable composition of the present invention is, for example, under a low temperature condition of about 2 ° C. to 8 ° C. (for example, in a refrigerator set at 5 ° C.) for a certain period of time (for example, as described above).
- a low temperature condition of about 2 ° C. to 8 ° C. (for example, in a refrigerator set at 5 ° C.) for a certain period of time (for example, as described above).
- the composition does not cause precipitation of coloring components even after storage (for example, for one month), that is, the composition can be stably stored.
- Typical examples of the dyes that can be applied to a living body used in the present invention include Blue No. 1 (Brilliant Blue FCF), Blue No. 2 (Indigo Carmine), and Green No. 3 (Fast Green FCF).
- Blue No. 1 (Brilliant Blue FCF)
- the concentration range thereof may be 0.0005% by mass or more and 0.05% by mass or less, and 0.001% by mass or more and 0.01% by mass. It may be:
- the term "combination" exists because the above-mentioned first agent (material) composition and second agent (material) composition are used in the present invention when applied to an object.
- the method for providing the first agent (material) composition and the second agent (material) composition is not particularly limited.
- the first material composition and the second material composition may be provided as a kit, or only the first material composition is provided, and the second material composition is separately prepared from a commercially available product and used. May be good.
- the first material composition may be in a solution state or a dry state at the time of storage (or at the time of provision), and in the dry state, it preferably contains a freeze-dried product of a monovalent metal salt of alginic acid.
- the first material composition may be encapsulated in a vial or a prefilled syringe.
- the first material composition and the second material composition are used as a kit, for example, (1) a blue to green dye that can be applied to a living body such as sodium alginate and blue No. 1 as the first material composition, and , A prefilled syringe containing a solution containing a monovalent metal salt such as sodium chloride, (2) an ampol containing a solution of a divalent or higher valent metal ionic compound such as a calcium chloride solution as a second material composition, (3) a syringe, (4) A kit containing an injection needle or the like in one package can be used. Further, for example, a double syringe capable of separately encapsulating two kinds of solutions may be provided by encapsulating (1) the solution of the first material composition and (2) the solution of the second material composition, respectively.
- the first agent (material) composition was applied to a subject in a fluid state, and the second agent (material) composition was applied to the subject. It is used so as to be in contact with the first agent (material) composition to gel at least a part thereof. Details such as application of the first material composition to the object, gelation of the first material composition, evaluation of the formation state of the gel film, and the like are as described in the mode for carrying out the invention.
- a step of applying a first agent (material) composition containing an alginic acid monovalent metal salt and a coloring component to a subject in a fluid state and a cross-linking of the alginic acid monovalent metal salt A step of bringing a second agent (material) composition containing a cross-linking agent having an action to perform an action into contact with the first agent (material) composition applied to the subject to gel at least a part thereof, and the subject.
- a method for treating the subject is provided, which comprises a step of evaluating the formation state of a gel film on the surface of the applied first agent (material) composition. Details of the first material composition, its application to the subject, the second material composition, the gelation of the first material composition, the evaluation of the formation state of the gel film, and the like are as described above.
- Example 1 Under arthroscopy, the articular cartilage defect was filled with a colored sodium alginate solution (2 w / w%). A 100 mM calcium chloride aqueous solution was brought into contact with the periphery including the liquid surface of the filled sodium alginate solution to gel the surface (formation of a gel film). After about 5 minutes, the area around the cartilage defect including the gel membrane surface was washed with physiological saline. After washing, when the formation of the gel film is insufficient, the outflow of sol-like colored alginate is observed.
- Example 2 Under arthroscopy, the articular cartilage defect was filled with a colored sodium alginate solution (2 w / w%). A 100 mM calcium chloride aqueous solution was brought into contact with the periphery including the liquid surface of the filled sodium alginate solution to gel the surface (formation of a gel film). After about 4 minutes, the gel film surface was touched with the tip of the syringe to confirm the formation of the gel film. You may touch the surface of the gel film with a sonde. When the formation of the gel film is inadequate, an outflow of sol-like colored alginate is observed.
- Example 3 Under arthroscopy, the articular cartilage defect was filled with a pH-6.5, purple sodium alginate solution (2 w / w%) colored with the pH-sensitive pigment anthocyanin. A 100 mM calcium chloride aqueous solution adjusted to pH 9.0 was brought into contact with the periphery including the liquid surface of the filled sodium alginate solution to gel the surface (formation of a gel film). The surface of the gel film that has come into contact with the calcium chloride aqueous solution changes from purple to blue, and the state of formation of the gel film can be evaluated.
- a first lumber composition (bioapplicable composition) can be prepared based on the formulations shown in the table below.
- the numerical value in the table means mass%.
- the preparation method can be carried out according to Test Example 1. It can also be prepared by methods commonly used in pharmaceuticals and medical devices.
- the second material composition can be a 0.1 mol / L calcium chloride solution.
- Blue No. 1 (Brilliant Blue FCF), which is a dye that can be applied to a living body, is added to a sodium alginate solution (2 w / w%) at concentrations of 0.001 w / w%, 0.004 w / w%, and 0.007 w / w%. Or, it was added so as to be 0.01 w / w%, colored, and 5 g each was dispensed into 3 glass vials. This was stored in a refrigerator set at 5 ° C., and sampled after 1 week, 2 weeks, and 1 month, and the sample was observed to confirm the presence or absence of pigment precipitation.
- Blue No. 1 (Brilliant Blue FCF) exhibited a bright blue color in the range of 0.001 w / w% to 0.01 w / w% in concentration, and was stored in a refrigerator for 1 month from the time of preparation. No precipitation of the dye was observed until later, and the color tone was stably maintained.
- the range of color values in the color system of the sodium alginate solution containing blue No. 1 is about 40 to 80 for L * (brightness), about -40 to -5 (green direction) for a *, and about b *. It turned out to be -60 to -20 (blue direction).
- Blue No. 2 (indigo carmine) exhibited a bright blue color at a concentration of 0.004 w / w%, and no pigment precipitation was observed after overnight refrigerated storage. However, the observation after 19 days showed the precipitation of the dye, and the precipitation disappeared when left at room temperature.
- Blue No. 1 (Brilliant Blue FCF) and Blue No. 2 (indigo carmine), which are dyes that can be applied to a living body, are both bright blue with respect to the sodium alginate solution. It became clear that the color tone can be given. In addition, it was clarified that Blue No. 1 (Brilliant Blue FCF) can give a more stable blue color tone than Blue No. 2 (Indigo Carmine).
- composition 1a Near the surface of the 1st agent (material) composition 1b Inside other than near the surface of the 1st agent (material) composition 2 Cartilage defect 3 2nd agent (material) composition
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Materials For Medical Uses (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
Description
また本発明の別の目的は、着色成分とアルギン酸1価金属塩を含有し、約2~8℃の低温で、一定期間(例えば1か月間等)の保存によっても着色成分の析出が生じない、すなわち、安定に保存可能な組成物を提供することである。
[1] アルギン酸1価金属塩を含有する第1剤(材)組成物と、アルギン酸1価金属塩を架橋する作用を有する架橋剤を含有する第2剤(材)組成物とを含み、前記第1剤(材)組成物を、流動性がある状態で対象に施与し、前記第2剤(材)組成物を、前記対象に施与した該第1剤(材)組成物に接触させてその少なくとも一部分をゲル化させるようにして用いるための、該組成物の組合せ物であって、前記第1剤(材)組成物が、更に着色成分を含有することにより、前記対象に施与した該第1剤(材)組成物の表面のゲル膜の形成状態を評価することができるようにしたことを特徴とする、該組合せ物。
[2] 前記ゲル膜の形成状態の評価が、前記対象に施与した該第1剤(材)組成物のうちの流動性がある状態の組成物の流出の有無の評価である、上記[1]に記載の組合せ物。
[3] 前記ゲル膜の形成状態の評価が、(1)前記対象に施与した該第1剤(材)組成物のゲル膜表面の洗浄後、及び/又は、(2)前記対象に施与した該第1剤(材)組成物のゲル膜表面への加圧後に行われる、上記[1]又は[2]に記載の組合せ物。
[4] 前記ゲル膜表面への加圧が、該ゲル膜表面に器具を接触させることにより行われる、上記[3]に記載の組合せ物。
[5] 前記対象は、骨組織、軟骨組織、骨軟骨組織、椎間板組織、半月板組織、靭帯からなる群から選択される少なくとも1種である、上記[1]~[4]のいずれか1項に記載の組合せ物。
[6] 前記第1材組成物が、前記着色成分として生体に施与可能な青色~緑色の色素を含有する、上記[1]~[5]のいずれか1項に記載の組合せ物。
[7] 前記第1材組成物の、分光色差計(光源:D65/2、測定モード:透過測定)での測定によるL*a*b*表色系における色彩値が、L*=40~80、a*=-40~0、b*=-60~-20である、上記[1]~[6]のいずれか1項に記載の組合せ物。
[8] 前記着色成分が、設定温度5℃の冷蔵庫で1か月間の保存後に析出が生じない濃度で含有されている、上記[1]~[7]のいずれか1項に記載の組合せ物。
[9] 前記第1材組成物の、設定温度5℃の冷蔵庫で1か月間保存後と保存前とを比べたときの、分光色差計(光源:D65/2、測定モード:透過測定)での測定によるL*a*b*表色系における色差ΔE値が35以下である、上記[1]~[8]のいずれか1項に記載の組合せ物。
[10] 前記第1材組成物が、2℃~8℃の条件下で保存可能である、上記[1]~[9]のいずれか1項に記載の組合せ物。
[11] 前記第1材組成物が、更に他の1価金属塩を含有する、上記[1]~[10]のいずれか1項に記載の組合せ物。
[12] 前記第1材組成物が、保存時に、溶液状態又は乾燥状態である、上記[1]~[11]のいずれか1項に記載の組合せ物。
[13] 前記第1材組成物が、アルギン酸1価金属塩、生体に施与可能な青色~緑色の色素、及び、塩化ナトリウムを含有し、2℃~8℃の条件下で保存可能な組成物であって、該組成物は保存時に溶液状態又は乾燥状態である、上記[1]~[12]のいずれか1項に記載の組合せ物。
[14] 前記着色成分は、0.0005質量%~0.05質量%の青色1号(ブリリアントブルーFCF)である、上記[1]~[13]のいずれか1項に記載の組合せ物。
[15] 前記着色成分は、該成分の媒体環境に応じた色調変化をもたらすものである、上記[1]~[13]のいずれか1項に記載の組合せ物。
[16] 前記媒体環境はpH環境である、上記[15]に記載の組合せ物。
[17] 前記第1材組成物はpH6以上pH8以下のゾル又は液体であり、前記第2材組成物はpH4以上pH6未満、又はpH8超pH12以下の液体である、上記[15]又は[16]に記載の組合せ物。
[18] 前記着色成分は、pH感受性色素、又は溶解遅延用素材で被覆されたpH感受性色素である、上記[15]~[17]のいずれか1項に記載の組合せ物。
[2-1] アルギン酸1価金属塩及び着色成分を含有する第1剤(材)組成物を、流動性がある状態で対象に施与する工程と、アルギン酸1価金属塩を架橋する作用を有する架橋剤を含有する第2剤(材)組成物を、前記対象に施与した該第1剤(材)組成物に接触させてその少なくとも一部分をゲル化させる工程と、前記対象に施与した該第1剤(材)組成物の表面のゲル膜の形成状態を評価する工程とを含む、該対象の処置方法。
[2-2] 前記ゲル膜の形成状態の評価が、前記対象に施与した該第1剤(材)組成物のうちの流動性がある状態の組成物の流出の有無の評価である、上記[2-1]に記載の方法。
[2-3] 前記ゲル膜の形成状態の評価が、(1)前記対象に施与した該第1剤(材)組成物のゲル膜表面の洗浄後、及び/又は、(2)前記対象に施与した該第1剤(材)組成物のゲル膜表面への加圧後に行われる、上記[2-1]又は[2-2]に記載の方法。
[2-4] 前記ゲル膜表面への加圧が、該ゲル膜表面に器具を接触させることにより行われる、上記[2-3]に記載の方法。
[2-5] 前記対象は、骨組織、軟骨組織、骨軟骨組織、椎間板組織、半月板組織、靭帯からなる群から選択される少なくとも1種である、上記[2-1]~[2-4]のいずれか1項に記載の方法。
[2-6] 前記第1材組成物が、前記着色成分として生体に施与可能な青色~緑色の色素を含有する、上記[2-1]~[2-5]のいずれか1項に記載の方法。
[2-7] 前記第1材組成物の、分光色差計(光源:D65/2、測定モード:透過測定)での測定によるL*a*b*表色系における色彩値が、L*=40~80、a*=-40~0、b*=-60~-20である、上記[2-1]~[2-6]のいずれか1項に記載の方法。
[2-8] 前記着色成分が、設定温度5℃の冷蔵庫で1か月間の保存後に析出が生じない濃度で含有されている、上記[2-1]~[2-7]のいずれか1項に記載の方法。
[2-9] 前記第1材組成物の、設定温度5℃の冷蔵庫で1か月間保存後と保存前とを比べたときの、分光色差計(光源:D65/2、測定モード:透過測定)での測定によるL*a*b*表色系における色差ΔE値が35以下である、上記[2-1]~[2-8]のいずれか1項に記載の方法。
[2-10] 前記第1材組成物が、2℃~8℃の条件下で保存可能である、上記[2-1]~[2-9]のいずれか1項に記載の方法。
[2-11] 前記第1材組成物が、更に他の1価金属塩を含有する、上記[2-1]~[2-10]のいずれか1項に記載の方法。
[2-12] 前記第1材組成物が、保存時に、溶液状態又は乾燥状態である、上記[2-1]~[2-11]のいずれか1項に記載の方法。
[2-13] 前記第1材組成物が、アルギン酸1価金属塩、生体に施与可能な青色~緑色の色素、及び、塩化ナトリウムを含有し、2℃~8℃の条件下で保存可能な組成物であって、該組成物は保存時に溶液状態又は乾燥状態である、上記[2-1]~[2-12]のいずれか1項に記載の方法。
[2-14] 前記着色成分は、0.0005質量%~0.05質量%の青色1号(ブリリアントブルーFCF)である、上記[2-1]~[2-13]のいずれか1項に記載の方法。
[3-1] アルギン酸1価金属塩及び着色成分を含有する第1剤(材)組成物を、流動性がある状態で対象に施与する工程と、アルギン酸1価金属塩を架橋する作用を有する架橋剤を含有する第2剤(材)組成物を、前記対象に施与した該第1剤(材)組成物に接触させてその少なくとも一部分をゲル化させる工程と、前記対象に施与した該第1剤(材)組成物の表面のゲル膜の形成状態を評価する工程とを含む、該対象の処置に用いるための該第1剤(材)及び第2剤(材)組成物の組合せ。
[4-1] アルギン酸1価金属塩を含有し、流動性がある状態で対象に施与されるための生体適用組成物であって、着色成分として、生体に施与可能な青色~緑色の色素を含有することを特徴とする、該生体適用組成物。
[4-2] 前記対象は、骨組織、軟骨組織、骨軟骨組織、椎間板組織、半月板組織、靭帯からなる群から選択される少なくとも1種である、[4-1]に記載の生体適用組成物。
[4-3] 前記生体適用組成物の、分光色差計(光源:D65/2、測定モード:透過測定)での測定によるL*a*b*表色系における色彩値が、L*=40~80、a*=-40~0、b*=-60~-20である、上記[4-1]又は[4-2]に記載の生体適用組成物。
[4-4] 前記着色成分が、設定温度5℃の冷蔵庫で1か月間の保存後に析出が生じない濃度で含有されている、上記[4-1]~[4-3]のいずれか1項に記載の生体適用組成物。
[4-5] 前記生体適用組成物の、設定温度5℃の冷蔵庫で1か月間保存後と保存前の組成物とを比べたときの、分光色差計(光源:D65/2、測定モード:透過測定)での測定によるL*a*b*表色系における色差ΔE値が35以下である、上記[4-1]~[4-4]のいずれか1項に記載の生体適用組成物。
[4-6] 前記生体適用組成物が、2℃~8℃の条件下で保存可能である、[4-1]~[4-5]のいずれか1項に記載の生体適用組成物。
[4-7] 前記アルギン酸1価金属塩は、GPC-MALS法により測定された重量平均分子量(絶対分子量)が1万~100万である、上記[4-1]~[4-6]のいずれか1項に記載の生体適用組成物。
[4-8] 前記アルギン酸1価金属塩が、低エンドトキシンアルギン酸1価金属塩である、上記[4-1]~[4-7]のいずれか1項に記載の生体適用組成物。
[4-9] 前記生体適用組成物が、更に他の1価金属塩を含有する、[4-1]~[4-8]のいずれか1項に記載の生体適用組成物。
[4-10] 前記生体適用組成物が、保存時に、溶液状態又は乾燥状態である、[4-1]~[4-9]のいずれか1項に記載の生体適用組成物。
[4-11] 前記生体適用組成物が、アルギン酸1価金属塩、生体に施与可能な青色~緑色の色素、及び、塩化ナトリウムを含有し、2℃~8℃の条件下で保存可能な組成物であって、該組成物は保存時に溶液状態又は乾燥状態である、[4-1]~[4-10]のいずれか1項に記載の生体適用組成物。
[4-12] 前記生体適用組成物は、対象に施与したときに少なくとも一部分がゲル化するようにして用いるための組成物である、[4-1]~[4-11]のいずれか1項に記載の生体適用組成物。
[4-13] 前記着色成分は、0.0005質量%~0.05質量%の青色1号(ブリリアントブルーFCF)である、上記[4-1]~[4-12]のいずれか1項に記載の生体適用組成物。
また、視認性を与える着色成分として国等の規制により生体への使用が許可されている色素、すなわち生体へ施与可能な色素を用いることにより、ヒト等に対して安全に使用することができる。
更に、約2℃~8℃の低温条件下で一定期間安定に保存可能な、着色成分及びアルギン酸1価金属塩を含有する組成物が提供されるため、安全性も高く、使い勝手がよい。
本発明の組合せ物、処置方法、及び、生体適用組成物は、上記のうちいずれか一つ以上の効果を有する。
また、いくつかの態様では、本発明に用いる着色成分は、国等の規制により生体への使用が許可されている色素、すなわち生体に施与可能な色素が好ましく、これについては後述する。
また、別の態様では、本発明に用いる着色成分は、本明細書の記載に準じて第1材組成物又は生体適用組成物を調製したときに、約2~8℃の低温条件下で、一定期間安定に保存可能な着色成分であることが好ましい。
アルギン酸は、生分解性の高分子多糖類であって、D‐マンヌロン酸(M)とL‐グルロン酸(G)という2種類のウロン酸が直鎖状に重合したポリマーである。より具体的には、D‐マンヌロン酸のホモポリマー画分(MM画分)、L‐グルロン酸のホモポリマー画分(GG画分)、及びD‐マンヌロン酸とL‐グルロン酸がランダムに配列した画分(MG画分)が任意に結合したブロック共重合体である。アルギン酸のD‐マンヌロン酸とL‐グルロン酸の構成比(M/G比)は、主に海藻等の由来となる生物の種類によって異なり、また、その生物の生育場所や季節による影響を受け、M/G比が約0.4の高G型からM/G比が約5の高M型まで高範囲にわたる。
本発明においては、アルギン酸1価金属塩を架橋する作用を有する架橋剤を用いる。具体的には、例えば、Ca2+、Mg2+、Ba2+、Sr2+などの2価以上の金属イオン化合物などが挙げられる。より具体的には、2価以上の金属イオン化合物として、CaCl2、MgCl2、CaSO4、BaCl2等を挙げることができるが、入手しやすいこと、ゲルの強度等の理由から、特に、CaCl2溶液が好ましい。
本発明における第1剤(材)組成物は、上記したアルギン酸1価金属塩及び本明細書に記載の着色成分を含有するものであればよく、特にその製剤的形態に制限はない。例えば、一旦溶液として調製したものを凍結乾燥等して乾燥状態で提供してもよい。ただし、生体組織等の対象への施与の際には一定の流動性と粘度の特性を備えている必要がある。よって、適用時にはゾル又は液体の状態(本明細書ではこれらを併せて「溶液状態」という)であるのが好ましい。そのための溶媒は特に制限されないが、例えば、精製水、蒸留水、イオン交換水、ミリQ水、生理食塩水、リン酸緩衝生理食塩水(PBS)などが挙げられる。これらは、滅菌されていることが好ましく、低エンドトキシン処理されたものが好ましい。例えば、ミリQ水をろ過滅菌して用いることができる。すなわち、第1材組成物は、その保存時(又は提供時)に、溶液状態又は乾燥状態であることが好ましい。
本発明における第2剤(材)組成物は、上記した架橋剤を含有するものであればよく、特にその製剤的形態に制限はない。例えば、一旦溶液として調製したものを凍結乾燥等して乾燥状態で提供してもよい。ただし、使用時にはシリンジ等の注入器を用いることが、操作性がよく、便利である。よって、適用時には液体の状態にして用いることが好ましい。そのための溶媒は特に制限されないが、例えば、精製水、蒸留水、イオン交換水、ミリQ水、生理食塩水、リン酸緩衝生理食塩水(PBS)などが挙げられる。これらは、滅菌されていることが好ましく、低エンドトキシン処理されたものが好ましい。例えば、ミリQ水をろ過滅菌して用いることができる。
本発明の別の観点においては、本発明は、更に、生体適用組成物を提供する。本明細書において「生体適用組成物」とは、上記に説明した組成物の組合せ物又は処置方法における第1材組成物のうち着色成分として、国等の規制により生体への使用が許可されている色素、すなわち生体に施与可能な色素を用いるものをいう。したがって「生体適用組成物」は「第1材組成物」の一形態であって、「第1材組成物」の語は「生体適用組成物」を含む意味で用いられ、特に断らない限り、「第1材組成物」は「生体適用組成物」に読み替えて用いることができる。すなわち、この生体適用組成物は、着色成分及びアルギン酸1価金属塩を含有し、流動性がある状態で対象に施与され、好ましくは、対象に施与したときに少なくとも一部分がゲル化するようにして用いられるものである。そして、着色成分を含有することにより、対象に施与したときのゲル化の様子を確実に視認することができるようにしており、更に、着色成分として国等の規制により生体への使用が許可されている色素、すなわち、生体へ施与可能な色素を用いることにより、ヒト等に対して安全に使用することができるようにしている。国等の規制により生体への施与が可能な色素としては、例えば、日本において、厚生労働省により、医薬品、医薬部外品、化粧品への使用が認められている色素、また、米国においてFDAにより、医薬品、医療機器、化粧品などへの使用が認められている色素等が挙げられる。また、着色成分は、生体適用組成物を、骨組織、軟骨組織、骨軟骨組織、椎間板組織、半月板組織、靭帯などに施与したときにゲル膜の形成状態を評価しやすいものであることが好ましく、識別性の観点から、青色~緑色の色素が好ましい。このような着色成分としては、例えば、緑色3号(ファストグリーンFCF)、青色1号(ブリリアントブルーFCF)、青色2号(インジゴカルミン)、緑色201号(アリザシンシアニングリーンF)、緑色202号(キニザリングリーンSS)、青色201号(インジゴ)、青色202号(パテントブルーNA)、青色203号(パテントブルーCA)などが挙げられ、より好ましくは、緑色3号(ファストグリーンFCF)、青色1号(ブリリアントブルーFCF)である。
本明細書において「組合せ物」とは、対象に施与するときに、前記の第1剤(材)組成物及び第2剤(材)組成物が本発明に用いられるために存在していればよく、第1剤(材)組成物と第2剤(材)組成物の提供方法は特に限定されない。例えば、第1材組成物と第2材組成物はキットとして提供されてもいいし、あるいは、第1材組成物のみ提供され、第2材組成物は別途市販品から調製して用いられてもよい。
本発明の組合せ物は、第1剤(材)組成物を、流動性がある状態で対象に施与し、第2剤(材)組成物を、前記対象に施与した第1剤(材)組成物に接触させてその少なくとも一部分をゲル化させるようにして用いられる。第1材組成物の対象への施与、第1材組成物のゲル化、ゲル膜の形成状態の評価などの詳細は、前記発明を実施するための形態等に記載のとおりである。
本発明において、アルギン酸1価金属塩及び着色成分を含有する第1剤(材)組成物を、流動性がある状態で対象に施与する工程と、アルギン酸1価金属塩を架橋する作用を有する架橋剤を含有する第2剤(材)組成物を、前記対象に施与した第1剤(材)組成物に接触させてその少なくとも一部分をゲル化させる工程と、前記対象に施与した該第1剤(材)組成物の表面のゲル膜の形成状態を評価する工程とを含む、該対象の処置方法が提供される。第1材組成物、その対象への施与、第2材組成物、第1材組成物のゲル化、ゲル膜の形成状態の評価等の詳細は、前記に記載のとおりである。
関節鏡視下、着色したアルギン酸ナトリウム溶液(2w/w%)を関節軟骨欠損部に充填した。充填したアルギン酸ナトリウム溶液の液面を含む周辺に100mM塩化カルシウム水溶液を接触させて、その表面をゲル化させた(ゲル膜の形成)。約5分後に、ゲル膜表面を含む軟骨欠損部周辺を生理食塩水で洗浄した。洗浄後、ゲル膜の形成が不十分なときは、ゾル状の着色したアルギン酸塩の流出が観察される。
関節鏡視下、着色したアルギン酸ナトリウム溶液(2w/w%)を関節軟骨欠損部に充填した。充填したアルギン酸ナトリウム溶液の液面を含む周辺に100mM塩化カルシウム水溶液を接触させて、その表面をゲル化させた(ゲル膜の形成)。約4分後に、注射器の先端でゲル膜表面に触れて、ゲル膜の形成を確認した。ゾンデ(消息子)でゲル膜表面に触れてもよい。ゲル膜の形成が不十分なときは、ゾル状の着色したアルギン酸塩の流出が観察される。
関節鏡視下、pH感受性色素アントシアニンで着色し、pH6.5、紫色のアルギン酸ナトリウム溶液(2w/w%)を関節軟骨欠損部に充填した。充填したアルギン酸ナトリウム溶液の液面を含む周辺に、pH9.0に調整した100mM塩化カルシウム水溶液を接触させて、その表面をゲル化させた(ゲル膜の形成)。塩化カルシウム水溶液が接触したゲル膜表面は、紫色から青色に変化し、ゲル膜の形成状態を評価することができる。
下記表に示す処方に基づいて、第1材組成物(生体適用組成物)を調製し得る。表中の数値は質量%を意味する。調製方法は試験例1に準じて行うことができる。また、一般的に医薬品や医療機器で用いられる方法で調製し得る。第2材組成物は、0.1mol/L塩化カルシウム溶液であり得る。
アルギン酸ナトリウム溶液(2w/w%)に、生体に施与可能な色素である青色1号(ブリリアントブルーFCF)を濃度0.001w/w%、0.004w/w%、0.007w/w%、又は0.01w/w%となるように添加して、着色し、ガラスバイアル3本に5gずつ分注した。これを5℃に設定した冷蔵庫で保存して、1週間、2週間、及び1ヵ月間経過後にサンプリングし、その試料を観察して色素析出の有無を確認した。また、分光色差計(「SE-6000」、日本電色工業株式会社製)を用いて各試料のL*、a*、b*値を測定した。測定は常温(15~25℃)の室内で行った。光源はD65/2とし、測定モードは透過測定とした。分光色差計は、サンプル測定前に、標品としての標準白色板(型番SE-38724,日本電色株式会社製)の測定値を、L*=100、a*=0,b*=0に調整した。
アルギン酸ナトリウム溶液(2w/w%)に、生体に施与可能な色素である青色2号(インジゴカルミン)を濃度0.004w/w%となるように添加して、着色し、シリンジに2gずつ分注した。この充填済みシリンジをネスト(シリンジ固定用グリッド付き容器)に入れ固定して、そのネストごと5℃に設定した冷蔵庫に保存し、一晩及び19日後経過後に、シリンジ内の試料を観察して色素析出の有無を確認した。
1a 第1剤(材)組成物の表面付近
1b 第1剤(材)組成物の表面付近以外の内部
2 軟骨欠損部
3 第2剤(材)組成物
Claims (14)
- アルギン酸1価金属塩を含有する第1材組成物と、アルギン酸1価金属塩を架橋する作用を有する架橋剤を含有する第2材組成物とを含み、前記第1材組成物を、流動性がある状態で対象に施与し、前記第2材組成物を、前記対象に施与した該第1材組成物に接触させてその少なくとも一部分をゲル化させるようにして用いるための、該組成物の組合せ物であって、前記第1材組成物が、更に着色成分を含有することにより、前記対象に施与した該第1材組成物の表面のゲル膜の形成状態を評価することができるようにしたことを特徴とする、該組合せ物。
- 前記ゲル膜の形成状態の評価が、前記対象に施与した該第1材組成物のうちの流動性がある状態の組成物の流出の有無の評価である、請求項1記載の組合せ物。
- 前記ゲル膜の形成状態の評価が、(1)前記対象に施与した該第1材組成物のゲル膜表面の洗浄後、及び/又は、(2)前記対象に施与した該第1材組成物のゲル膜表面への加圧後に行われる、請求項1又は2記載の組合せ物。
- 前記ゲル膜表面への加圧が、該ゲル膜表面に器具を接触させることにより行われる、請求項3記載の組合せ物。
- 前記対象は、骨組織、軟骨組織、骨軟骨組織、椎間板組織、半月板組織、靭帯からなる群から選択される少なくとも1種である、請求項1~4のいずれか1項に記載の組合せ物。
- 前記第1材組成物が、前記着色成分として生体に施与可能な青色~緑色の色素を含有する、請求項1~5のいずれか1項に記載の組合せ物。
- 前記第1材組成物の、分光色差計(光源:D65/2、測定モード:透過測定)での測定によるL*a*b*表色系における色彩値が、L*=40~80、a*=-40~0、b*=-60~-20である、請求項1~6のいずれか1項に記載の組合せ物。
- 前記着色成分が、設定温度5℃の冷蔵庫で1か月間の保存後に析出が生じない濃度で含有されている、請求項1~7のいずれか1項に記載の組合せ物。
- 前記第1材組成物の、設定温度5℃の冷蔵庫で1か月間保存後と保存前とを比べたときの、分光色差計(光源:D65/2、測定モード:透過測定)での測定によるL*a*b*表色系における色差ΔE値が35以下である、請求項1~8のいずれか1項に記載の組合せ物。
- 前記第1材組成物が、2℃~8℃の条件下で保存可能である、請求項1~9のいずれか1項に記載の組合せ物。
- 前記第1材組成物が、更に他の1価金属塩を含有する、請求項1~10のいずれか1項に記載の組合せ物。
- 前記第1材組成物が、保存時に、溶液状態又は乾燥状態である、請求項1~11のいずれか1項に記載の組合せ物。
- 前記第1材組成物が、アルギン酸1価金属塩、生体に施与可能な青色~緑色の色素、及び、塩化ナトリウムを含有し、2℃~8℃の条件下で保存可能な組成物であって、該組成物は保存時に溶液状態又は乾燥状態である、請求項1~12のいずれか1項に記載の組合せ物。
- 前記着色成分は、0.0005質量%~0.05質量%の青色1号(ブリリアントブルーFCF)である、請求項1~13のいずれか1項に記載の組合せ物。
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2021206966A AU2021206966A1 (en) | 2020-01-14 | 2021-01-13 | Combination and method for treating subject using alginic acid salt |
JP2021571198A JPWO2021145325A1 (ja) | 2020-01-14 | 2021-01-13 | |
KR1020227023727A KR20220127821A (ko) | 2020-01-14 | 2021-01-13 | 알긴산염을 사용한 대상의 처치를 위한 조합 및 방법 |
CN202180008759.2A CN114980937A (zh) | 2020-01-14 | 2021-01-13 | 用于使用了褐藻酸盐的对象的处置的组合和方法 |
US17/792,099 US20230045844A1 (en) | 2020-01-14 | 2021-01-13 | Combination and method for treating subject using alginate |
EP21741903.5A EP4074349A4 (en) | 2020-01-14 | 2021-01-13 | COMBINATION AND METHOD FOR TREATING SUBJECTS WITH ALGIC ACID SALT |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020-003614 | 2020-01-14 | ||
JP2020003614 | 2020-01-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021145325A1 true WO2021145325A1 (ja) | 2021-07-22 |
Family
ID=76863792
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2021/000754 WO2021145325A1 (ja) | 2020-01-14 | 2021-01-13 | アルギン酸塩を使用した対象の処置のための組合せ及び方法 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20230045844A1 (ja) |
EP (1) | EP4074349A4 (ja) |
JP (1) | JPWO2021145325A1 (ja) |
KR (1) | KR20220127821A (ja) |
CN (1) | CN114980937A (ja) |
AU (1) | AU2021206966A1 (ja) |
WO (1) | WO2021145325A1 (ja) |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993013136A1 (en) | 1991-12-20 | 1993-07-08 | Howmedica Inc. | Ultra-pure polysaccharide materials for medical use |
JPH08269102A (ja) | 1995-03-30 | 1996-10-15 | Shiseido Co Ltd | エンドトキシンフリーのβ1,3−グルカン及びその製造法並びに医療用ゲル素材 |
US5589591A (en) | 1986-07-03 | 1996-12-31 | Advanced Magnetics, Inc. | Endotoxin-free polysaccharides |
JPH09324001A (ja) | 1996-04-02 | 1997-12-16 | Kyowa Hakko Kogyo Co Ltd | ヒアルロン酸ナトリウムの精製法 |
JP2002104996A (ja) | 2000-09-25 | 2002-04-10 | Mochida Pharmaceut Co Ltd | 色素含有止血用組成物 |
JP2002530440A (ja) | 1998-11-13 | 2002-09-17 | シーピー ケルコ ユー.エス.インク. | エンドトキシンレベルが低い生体高分子塩、その生体高分子組成物およびこれを製造する方法 |
JP2005036036A (ja) | 2003-07-16 | 2005-02-10 | Tanabe Seiyaku Co Ltd | エンドトキシン除去方法 |
JP4740369B2 (ja) | 2007-02-21 | 2011-08-03 | 持田製薬株式会社 | 軟骨疾患治療用組成物 |
JP2011246714A (ja) * | 2010-05-27 | 2011-12-08 | Confluent Surgical Inc | 様々な架橋度を有するヒドロゲル移植物 |
JP2013514152A (ja) * | 2009-12-15 | 2013-04-25 | インセプト・リミテッド・ライアビリティ・カンパニー | インプラントおよび生体分解性基準マーカー |
WO2017163603A1 (ja) * | 2016-03-23 | 2017-09-28 | 国立大学法人北海道大学 | 椎間板治療用組成物 |
JP2017537130A (ja) * | 2014-12-10 | 2017-12-14 | インセプト・リミテッド・ライアビリティ・カンパニーIncept,Llc | ハイドロゲル薬物送達インプラント |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6818018B1 (en) * | 1998-08-14 | 2004-11-16 | Incept Llc | In situ polymerizable hydrogels |
JP6727623B2 (ja) * | 2016-11-07 | 2020-07-22 | 国立大学法人大阪大学 | 角結膜被覆シート作製用キット及び角結膜被覆シートの作製方法 |
-
2021
- 2021-01-13 US US17/792,099 patent/US20230045844A1/en active Pending
- 2021-01-13 JP JP2021571198A patent/JPWO2021145325A1/ja active Pending
- 2021-01-13 AU AU2021206966A patent/AU2021206966A1/en active Pending
- 2021-01-13 CN CN202180008759.2A patent/CN114980937A/zh active Pending
- 2021-01-13 EP EP21741903.5A patent/EP4074349A4/en active Pending
- 2021-01-13 KR KR1020227023727A patent/KR20220127821A/ko unknown
- 2021-01-13 WO PCT/JP2021/000754 patent/WO2021145325A1/ja unknown
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5589591A (en) | 1986-07-03 | 1996-12-31 | Advanced Magnetics, Inc. | Endotoxin-free polysaccharides |
WO1993013136A1 (en) | 1991-12-20 | 1993-07-08 | Howmedica Inc. | Ultra-pure polysaccharide materials for medical use |
JPH08269102A (ja) | 1995-03-30 | 1996-10-15 | Shiseido Co Ltd | エンドトキシンフリーのβ1,3−グルカン及びその製造法並びに医療用ゲル素材 |
JPH09324001A (ja) | 1996-04-02 | 1997-12-16 | Kyowa Hakko Kogyo Co Ltd | ヒアルロン酸ナトリウムの精製法 |
JP2002530440A (ja) | 1998-11-13 | 2002-09-17 | シーピー ケルコ ユー.エス.インク. | エンドトキシンレベルが低い生体高分子塩、その生体高分子組成物およびこれを製造する方法 |
JP2002104996A (ja) | 2000-09-25 | 2002-04-10 | Mochida Pharmaceut Co Ltd | 色素含有止血用組成物 |
JP2005036036A (ja) | 2003-07-16 | 2005-02-10 | Tanabe Seiyaku Co Ltd | エンドトキシン除去方法 |
JP4740369B2 (ja) | 2007-02-21 | 2011-08-03 | 持田製薬株式会社 | 軟骨疾患治療用組成物 |
JP2013514152A (ja) * | 2009-12-15 | 2013-04-25 | インセプト・リミテッド・ライアビリティ・カンパニー | インプラントおよび生体分解性基準マーカー |
JP2011246714A (ja) * | 2010-05-27 | 2011-12-08 | Confluent Surgical Inc | 様々な架橋度を有するヒドロゲル移植物 |
JP2017537130A (ja) * | 2014-12-10 | 2017-12-14 | インセプト・リミテッド・ライアビリティ・カンパニーIncept,Llc | ハイドロゲル薬物送達インプラント |
WO2017163603A1 (ja) * | 2016-03-23 | 2017-09-28 | 国立大学法人北海道大学 | 椎間板治療用組成物 |
JP6487110B2 (ja) | 2016-03-23 | 2019-03-20 | 国立大学法人北海道大学 | 椎間板治療用組成物 |
Non-Patent Citations (3)
Title |
---|
"Japanese Pharmacopoeia" |
APPL MICROBIOL BIOTECHNOL, vol. 40, 1994, pages 638 - 643 |
See also references of EP4074349A4 |
Also Published As
Publication number | Publication date |
---|---|
AU2021206966A1 (en) | 2022-08-04 |
US20230045844A1 (en) | 2023-02-16 |
CN114980937A (zh) | 2022-08-30 |
JPWO2021145325A1 (ja) | 2021-07-22 |
KR20220127821A (ko) | 2022-09-20 |
EP4074349A1 (en) | 2022-10-19 |
EP4074349A4 (en) | 2024-02-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6907254B2 (ja) | 椎間板治療用組成物 | |
CN104906126B (zh) | 用于治疗软骨疾病的组合物 | |
BRPI0714386A2 (pt) | hidrogel, conta, mÉtodos para produzir um hidrogel ou uma conta, para implantar uma conta ou dispositivo mÉdico implantÁvel e cÉlulas em um paciente, para bloquear vasos sanguÍneos, e para formar um hidrogel, dispositivo mÉdico implantÁvel, formulaÇço de liberaÇço de droga, agente de contraste ou material radioopaco, e, composiÇço terapÊutica embàlica | |
KR102434024B1 (ko) | 알지네이트/콜라겐 히드로겔 중의 fgf-18 제형물 | |
WO2016114355A1 (ja) | 癒着防止用組成物 | |
US20160067309A1 (en) | Composition for regeneration of cartilage | |
WO2021145325A1 (ja) | アルギン酸塩を使用した対象の処置のための組合せ及び方法 | |
Lehnert et al. | Tailoring the assembly of collagen fibers in alginate microspheres | |
US20120088721A1 (en) | Cartilage Repair | |
WO2022102093A1 (ja) | 椎間板性疼痛抑制用組成物 | |
JP2024511421A (ja) | 組織を分離するための流体ゲルを含む組成物 | |
CN110520165A (zh) | 纤维软骨组织损伤治疗用组合物 | |
Warren et al. | Injectable peptide-glycosaminoglycan hydrogels for soft tissue repair: in vitro assessment for nucleus augmentation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21741903 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2021571198 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2021206966 Country of ref document: AU Date of ref document: 20210113 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2021741903 Country of ref document: EP Effective date: 20220711 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |